Trending...
- Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
- Mister Omaha Tries The Turf At Lone Star Park
- The Mapping Software Behind America's Viral Maps Just Got Faster and Smarter
* A GLP ~ A new study presented at the Alzheimer's Association International Conference® (AAIC®) 2024 has revealed promising results for a drug that may slow cognitive decline in individuals with Alzheimer's disease. The Phase 2b clinical trial data, reported by researchers today in Philadelphia and online, suggests that a glucagon-like peptide-1 (GLP-1) drug can protect the brain and potentially reduce cognitive decline.
GLP-1 receptor agonists are drugs that mimic the natural hormone glucagon-like peptide released by the stomach after eating. These drugs are commonly used to manage diabetes, promote weight loss, and lower the risk of heart disease, stroke, and kidney disease. Previous research in animal models of Alzheimer's disease has shown that GLP-1 receptor agonists may have neuroprotective effects, reduce early forms of amyloid (a protein associated with Alzheimer's), normalize glucose processing in the brain, and improve memory and learning. The specific GLP-1 receptor agonist studied in this trial was liraglutide, manufactured by Novo Nordisk.
The new research presented at AAIC 2024 suggests that liraglutide may have a protective effect on the brains of individuals with mild Alzheimer's disease. After one year of treatment, those who received liraglutide showed an 18% reduction in cognitive decline compared to those who received a placebo. This was measured by slowing the shrinking of key areas of the brain responsible for memory, learning, language, and decision-making.
More on The PennZone
Maria C. Carrillo, Ph.D., chief science officer and medical affairs lead for the Alzheimer's Association, expressed hope for these findings: "We are in an era of unprecedented promise with new treatments in development that may slow or even prevent cognitive decline due to Alzheimer's disease." She also noted that repurposing drugs already approved for other conditions has advantages such as providing data from previous research and practical use.
The Alzheimer's Association has invested over $82 million in the Part the Cloud research grants program, which has supported 68 clinical trials targeting various compounds, including repurposed drugs, to address different aspects of the disease.
The ELAD trial, led by Prof. Paul Edison, M.D., Ph.D., from Imperial College London, included 204 patients with mild Alzheimer's disease from 24 clinics in the United Kingdom. The participants were randomly assigned to receive either a daily subcutaneous injection of up to 1.8 mg of liraglutide or a placebo for one year. Before and after the study, all patients underwent magnetic resonance imaging (MRI) to evaluate brain structure and volumes, glucose metabolism PET scans, and detailed memory testing.
More on The PennZone
While the primary endpoint of change in cerebral glucose metabolic rate was not met, the secondary endpoint of change in clinical and cognitive measures showed significant benefit for those who received liraglutide. Additionally, an exploratory endpoint of brain volume also showed statistically significant improvement.
Dr. Edison explained that the slower loss of brain volume seen in those who received liraglutide suggests that the drug may protect the brain similarly to how statins protect the heart. He also noted that further research is needed to fully understand how liraglutide works but suggested that it may reduce inflammation in the brain, lower insulin resistance, and improve communication between nerve cells.
In terms of cognitive function, researchers found that those who received liraglutide had an 18% slower decline compared to those who received a placebo. This was measured by a composite score of 18 different tests assessing memory, comprehension, language, and spatial orientation.
Overall, this study provides hope for potential new treatments for Alzheimer's disease and highlights the importance of repurposing drugs already approved for other conditions. Further research is needed to fully understand how liraglutide works and its potential as a treatment for Alzheimer's disease.
GLP-1 receptor agonists are drugs that mimic the natural hormone glucagon-like peptide released by the stomach after eating. These drugs are commonly used to manage diabetes, promote weight loss, and lower the risk of heart disease, stroke, and kidney disease. Previous research in animal models of Alzheimer's disease has shown that GLP-1 receptor agonists may have neuroprotective effects, reduce early forms of amyloid (a protein associated with Alzheimer's), normalize glucose processing in the brain, and improve memory and learning. The specific GLP-1 receptor agonist studied in this trial was liraglutide, manufactured by Novo Nordisk.
The new research presented at AAIC 2024 suggests that liraglutide may have a protective effect on the brains of individuals with mild Alzheimer's disease. After one year of treatment, those who received liraglutide showed an 18% reduction in cognitive decline compared to those who received a placebo. This was measured by slowing the shrinking of key areas of the brain responsible for memory, learning, language, and decision-making.
More on The PennZone
- Disruptor Creations Pioneers New MicroAdventure Series with TravelSpike
- Hawk Hill Pictures Brings Ukrainian-Language War Drama BUCHA to North American Audiences
- eCopier Solutions Surpasses 3,000 Five-Star Google Reviews and Maintains Perfect Five-Star Rating
- Creative Investment Research Welcomes Supreme Court Decision Protecting Federal Reserve Independence While Calling for Continued Accountability
- Rebecca Francis Team Ranks Among Top 1.5% of Teams and Agents Nationwide
Maria C. Carrillo, Ph.D., chief science officer and medical affairs lead for the Alzheimer's Association, expressed hope for these findings: "We are in an era of unprecedented promise with new treatments in development that may slow or even prevent cognitive decline due to Alzheimer's disease." She also noted that repurposing drugs already approved for other conditions has advantages such as providing data from previous research and practical use.
The Alzheimer's Association has invested over $82 million in the Part the Cloud research grants program, which has supported 68 clinical trials targeting various compounds, including repurposed drugs, to address different aspects of the disease.
The ELAD trial, led by Prof. Paul Edison, M.D., Ph.D., from Imperial College London, included 204 patients with mild Alzheimer's disease from 24 clinics in the United Kingdom. The participants were randomly assigned to receive either a daily subcutaneous injection of up to 1.8 mg of liraglutide or a placebo for one year. Before and after the study, all patients underwent magnetic resonance imaging (MRI) to evaluate brain structure and volumes, glucose metabolism PET scans, and detailed memory testing.
More on The PennZone
- Ascent Solar Technologies (N A S D A Q: ASTI): Positioned at the Intersection of the New Space Economy, Defense Innovation and Next-Generation Energy
- Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
- Morrisville & Cary Education Centers Honored with National Award
- AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
- Henri-Lloyd Launches Sail Free to Break Down Barriers to Sailing
While the primary endpoint of change in cerebral glucose metabolic rate was not met, the secondary endpoint of change in clinical and cognitive measures showed significant benefit for those who received liraglutide. Additionally, an exploratory endpoint of brain volume also showed statistically significant improvement.
Dr. Edison explained that the slower loss of brain volume seen in those who received liraglutide suggests that the drug may protect the brain similarly to how statins protect the heart. He also noted that further research is needed to fully understand how liraglutide works but suggested that it may reduce inflammation in the brain, lower insulin resistance, and improve communication between nerve cells.
In terms of cognitive function, researchers found that those who received liraglutide had an 18% slower decline compared to those who received a placebo. This was measured by a composite score of 18 different tests assessing memory, comprehension, language, and spatial orientation.
Overall, this study provides hope for potential new treatments for Alzheimer's disease and highlights the importance of repurposing drugs already approved for other conditions. Further research is needed to fully understand how liraglutide works and its potential as a treatment for Alzheimer's disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- Verbica Challenges Panetta to a Televised Debate on the Issues
- Grace Montessori School Raises $115,000 for Student Scholarships and Enhanced Programming
- Salt Lake City Families Turn to Private Autopsy Services for Faster Answers After Unexpected Loss
- K2 Integrity's U.S. and EMEA Teams Again Recognized in Chambers and Partners 2026 Guides
- Connecta Satellite Solutions Ready to Support Emergency Communications Following the Venezuela Earthquake
- Rare 1933 Harold Weston painting will be auctioned to benefit the Keene Valley Library
- $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
- HomeCentris Home Health Achieves 5-Star CMS Rating
- Adsoptia Launches AI-Powered Optimization Platform for a New Era of Autonomous Marketing Decisions
- Heritage at Manalapan Announces New Incentive: Included Finished Basement on Select Homesites
- Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders
- The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
- Cango Mobility x Hikvision Announce Strategic Partnership
- Institute of Emerging Minds Publishes Framework for Glymphatic Clearance and Cognitive Optimization
- HomeCentris Healthcare Signs Definitive Agreement to Acquire S&K Holdings, Expanding Mid Atlantic Platform
- Nayarit Strengthens Its Position as a Global Surf Destination; Sayulita to Become Mexico's First Official Surf City
- Century Fasteners de Mexico Exhibiting at 2026 Farnborough International Airshow
- George Martinez Completes Community Re-distribution Initiative, Returning $5,000 In Campaign Resources To Anchorage Nonprofits
- Mister Omaha Tries The Turf At Lone Star Park
- Andrew D. Levine Releases The Lily Network, an Indian Noir Mystery of Power, Paperwork & Murder